Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Roger Henriksson
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrew Bottomley
No relevant relationships to disclose
Warren Mason
Consultant or Advisory Role - Roche
Frank Saran
Consultant or Advisory Role - Roche
Wolfgang Wick
Consultant or Advisory Role - Lilly; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; MSD
Ryo Nishikawa
Consultant or Advisory Role - Roche
Timothy Francis Cloughesy
Consultant or Advisory Role - Apogenics; Celgene; Genentech; Merck; Merck Serono; NewGen Therapeutics; Roche; Tocagen
Antoine F Carpentier
Consultant or Advisory Role - Roche
Honoraria - Roche
Khe Hoang-Xuan
Consultant or Advisory Role - Roche (U)
Petr Kavan
No relevant relationships to disclose
Dana Cernea
No relevant relationships to disclose
Alba Ariela Brandes
No relevant relationships to disclose
Magalie Hilton
Employment or Leadership Position - Roche
Ana Maria Abajo Guijarro
Employment or Leadership Position - Roche
Arliene Ravelo
Employment or Leadership Position - Roche
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche